Session Title: Quick Fire Free Paper 4
Session Date/Time: Sunday 14/09/2014 | 08:00-10:00
Paper Time: 09:15
Venue: Boulevard B
First Author: : M.Hosny EGYPT
Co Author(s): : M. Zayed A. Shalaby
We studied the effect of an intracameral Bevacizumab injection on the corneal endothelium and iris neovessels (INV).
Department of Ophthalmology, Cairo University
Twenty eyes of 20 patients were enrolled in this study. Group (A) included 10 eyes of 10 patients with an average age of 52.1 ± 13.17 years. Group (A) patients underwent intracameral Bevacizumab injections at a concentration of 1.25 mg/0.05 mL Group (B) served as a control group and included 10 eyes of 10 patients with an average age of 45.5 ± 9.8 years. Group (B) had panretinal laser photocoagulation. Gonioscopy, iris fluorescein angiography, pachymetry and specular microscopy were recorded preoperatively and postoperatively.
INVs started to regress clinically within the first 2 days after the injection and regressed completely by the end of the fourth week in Group (A). Reduction in INV leakage started one week after injection, and resolved in 8 eyes by the end of the fourth week in Group (A). In Group (B) INVs started to regress clinically in all 10 eyes 7 days after treatment and disappeared totally in 6 out of the 10 eyes after 3 weeks. Complete resolution of INV leakage occurred in 5 eyes after 3 weeks. The mean endothelial cell loss was 3.95% ± 6.78 in Group (A) and 3.18% ± 2.77 in Group (B) after 4 months.
Intracameral Bevacizumab injection is effective for treatment of iris neovascularization and safe for corneal endothelial cells.